Live from the NIH registry
Studies recruiting near Lubbock right now
Top 25 of 109 recruiting studies, sorted by proximity — each links to its official registry page
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
Phase 3
Interventional 762 participants sought
89bio Clinical Study Site — Lubbock, Texas (2.1 mi)
· Sponsor: 89bio, Inc.
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
Psoriatic Arthritis
Phase 3
Interventional 1,088 participants sought
West Texas Clinical Research — Lubbock, Texas (2.1 mi)
· Sponsor: Takeda
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Breast Neoplasms, Triple Negative Breast Neoplasms
Phase 3
Interventional 2,400 participants sought
Texas Tech University Health Sciences Center ( Site 0087) — Lubbock, Texas (2.1 mi)
· Sponsor: Merck Sharp & Dohme LLC
Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk
Peripheral Arterial Disease, Atherosclerosis of Extremities
Phase 3
Interventional 6,150 participants sought
Texas Tech University Health Sciences — Lubbock, Texas (2.1 mi)
· Sponsor: Population Health Research Institute
Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy
Radiation Retinopathy, Visual Impairment
Phase 3
Interventional 600 participants sought
Texas Retina Associates — Lubbock, Texas (2.1 mi)
· Sponsor: Jaeb Center for Health Research
Penicillin Allergy Delabeling After a One-Dose Versus Two-Dose Graded Direct Oral Challenge
Penicillin Allergy
Phase 3
Interventional 380 participants sought
Texas Tech University Health Sciences Center — Lubbock, Texas (2.1 mi)
· Sponsor: James Tarbox, MD
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
Relapsing Multiple Sclerosis, Multiple Sclerosis
N/A
Observational 2,000 participants sought
TG Therapeutics Investigational Trial Site — Lubbock, Texas (2.1 mi)
· Sponsor: TG Therapeutics, Inc.
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Breast Cancer
Phase 3
Interventional 3,960 participants sought
UMC Cancer Center / UMC Health System — Lubbock, Texas (2.1 mi)
· Sponsor: NRG Oncology
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
Breast Cancer
N/A
Observational 1,800 participants sought
Joe Arrington Cancer Research & Treatment Center — Lubbock, Texas (2.1 mi)
· Sponsor: Exact Sciences Corporation
A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
High Grade Osteosarcoma, Localized Osteosarcoma
Phase 2, Phase 3
Interventional 1,122 participants sought
Covenant Children's Hospital — Lubbock, Texas (2.1 mi)
· Sponsor: National Cancer Institute (NCI)
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
Clostridium Difficile, Clostridium Difficile Infections
Phase 3
Interventional 852 participants sought
GI Alliance — Lubbock, Texas (2.1 mi)
· Sponsor: Vedanta Biosciences, Inc.
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
Phase 3
Interventional 720 participants sought
Research Site — Lubbock, Texas (2.1 mi)
· Sponsor: Arcus Biosciences, Inc.
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
Anaplastic Kidney Wilms Tumor, Recurrent Kidney Wilms Tumor
Phase 2
Interventional 256 participants sought
Covenant Children's Hospital — Lubbock, Texas (2.1 mi)
· Sponsor: Children's Oncology Group
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
Chronic Kidney Disease
Phase 3
Interventional 7,000 participants sought
Research Site — Lubbock, Texas (2.1 mi)
· Sponsor: AstraZeneca
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7
Phase 2, Phase 3
Interventional 613 participants sought
Covenant Medical Center-Lakeside — Lubbock, Texas (2.1 mi)
· Sponsor: National Cancer Institute (NCI)
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma
Phase 3
Interventional 1,524 participants sought
Covenant Medical Center-Lakeside — Lubbock, Texas (2.1 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma
Phase 2
Interventional 80 participants sought
Covenant Children's Hospital — Lubbock, Texas (2.1 mi)
· Sponsor: Children's Oncology Group
Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis- Magnetic Resonance Imaging
Stroke, Intracranial Atherosclerotic Stenosis (ICAS)
N/A
Observational 300 participants sought
Covenant Medical Center — Lubbock, Texas (2.1 mi)
· Sponsor: Yale University
Snacks and Brain Health
Cognitive Assessment, Psychological Function
Phase 1, Phase 2
Interventional 60 participants sought
Texas Tech University Health Sciences Center — Lubbock, Texas (2.1 mi)
· Sponsor: Texas Tech University Health Sciences Center
Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors
Recurrent or Refractory Solid Tumors, Ewing Sarcoma
Phase 1
Interventional 30 participants sought
Texas Tech University Health Sciences Center — Lubbock, Texas (2.1 mi)
· Sponsor: South Plains Oncology Consortium
EEG-Guided Binaural Beat Audio to Reduce Performance-Related Stress and Improve Cognition
Cognitive Abilities, Performance
N/A
Interventional 32 participants sought
Texas Tech University — Lubbock, Texas (2.1 mi)
· Sponsor: Texas Tech University Health Sciences Center
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
Arthritis, Psoriatic
Phase 3
Interventional 600 participants sought
Clinical Site — Lubbock, Texas (2.1 mi)
· Sponsor: MoonLake Immunotherapeutics AG
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
Ulcerative Colitis
Phase 2
Interventional 252 participants sought
GI Alliance - Lubbock — Lubbock, Texas (2.1 mi)
· Sponsor: Eli Lilly and Company
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia
Phase 2
Interventional 461 participants sought
Covenant Children's Hospital — Lubbock, Texas (2.1 mi)
· Sponsor: National Cancer Institute (NCI)
Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature
Peripheral Vascular Diseases
N/A
Observational 5,000 participants sought
Texas Tech University Health Sciences Center — Lubbock, Texas (2.1 mi)
· Sponsor: Boston Scientific Corporation